Browse > Article
http://dx.doi.org/10.5808/gi.22042

The relationship of E-selectin single-nucleotide polymorphisms with breast cancer in Iraqi Arab women  

Bilal Fadil Zakariya (Department of Biology, Institute of Sciences, Cankiri Karatekin University)
Asmaa M. Salih Almohaidi (Department of Biology, College of Science for Women, University of Baghdad)
Secil Akilli Simsek (Department of Biology, Institute of Sciences, Cankiri Karatekin University)
Safaa A. Al-Waysi (Department of Microbiology, Medical City Teaching Hospital)
Wijdan H. Al-Dabbagh (Department of Oncology, Medical City Teaching Hospital)
Areege Mustafa Kamal (Department of Pathology/Oncology, Medical City Teaching Hospital)
Abstract
Breast cancer (BC) is a significant threat to female health, with both modifiable and non-modifiable risk factors. It is essential to monitor patients regularly and to raise population awareness. Increasing research also suggests that E-selectin (SELE) may increase tumor angiogenesis and the development of cancer. This study investigated SELE single-nucleotide polymorphisms (SNPs) in the following positions: rs5367T/C, rs5368C/T, rs5362T/G, and rs5362T/C. Using polymerase chain reaction, significant differences in allele and genotype frequencies were found between BC patients and controls. Position rs5368 was associated with an increased risk of BC for the CT and TT genotypes, with odds ratios (ORs) of 16.3 and 6.90 (Fisher probability = 0.0001, p = 0.005). Women with the T allele had a 19.3-fold higher incidence of BC, while allele C may be a protective allele against BC (OR, 0.05). Heterozygous genotypes at rs5367, rs5362, and rs5362 were significantly more common in BC patients, with ORs of 5.70, 4.50, and 3.80, respectively. These SNPs may be associated with the risk of BC, because the frequency of mutant alleles was significantly higher in patients (OR: 4.26, 3.83, and 4.30, respectively) than in controls (OR: 0.23, 0.30, and 0.20, respectively). These SNPs may be considered a common genotype in the Iraqi population, with the wild-type allele having a protective fraction and the mutant allele having an environmental fraction. The results also revealed a 2-fold increase in gene expression in BC patients compared to controls, with a significant effect (p = 0.017). This study's findings confirm the importance of SELE polymorphisms in cancer risk prediction.
Keywords
breast neoplasms; E-selectin; expression; polymorphism;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 GHDx. Ministry of Health (Iraq). Seattle: Institute for Health Metrics and Evaluation, 2022. Accessed 2022 Apr 30. Available from: https://ghdx.healthdata.org/organizations/ministry-health-iraq.
2 Alessandro R, Seidita G, Flugy AM, Damiani F, Russo A, Corrado C, et al. Role of S128R polymorphism of E-selectin in colon metastasis formation. Int J Cancer 2007;121:528-535.   DOI
3 Yoshida M, Takano Y, Sasaoka T, Izumi T, Kimura A. E-selectin polymorphism associated with myocardial infarction causes enhanced leukocyte-endothelial interactions under flow conditions. Arterioscler Thromb Vasc Biol 2003;23:783-788.   DOI
4 Tang L, Xiong T, Jia Q, He Q, Tong X, Peng Y, et al. Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies. Tumour Biol 2014;35:3009-3016.   DOI
5 Naidu R, Har YC, Taib NA. Polymorphic variant Ser128Arg of E-Selectin is associated with breast cancer risk and high grade tumors. Onkologie 2011;34:592-597.   DOI
6 Cheng DY, Hao YW, Zhou WL, Ma YR. E-selectin S128R polymorphism is associated with cancer risk: a meta-analysis. Asian Pac J Cancer Prev 2014;15:3247-3252.   DOI
7 Narita T, Kawasaki-Kimura N, Matsuura N, Funahashi H, Kannagi R. Adhesion of human breast cancer cells to vascular endothelium mediated by sialyl LewisX/E-selectin. Breast Cancer 1996;3:19-23.   DOI
8 Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc 2010;2010:pdb prot5439.
9 Hardy-Weinberg equilibrium calculator for 3 alleles. Had2Know, 2022. Accessed 2022 Apr 30. Available from: https://www.had2know.org/academics/hardy-weinberg-equilibrium-calculator-3-alleles.htm.
10 Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13:1141-1151.   DOI
11 Hudis C, Dannenberg A. Obesity and breast cancer: narrowing the focus. JAMA Oncol 2015;1:622-623.   DOI
12 Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987;45:277-282.   DOI
13 Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin 2017;67:378-397.   DOI
14 Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun 2013;4:1449.
15 Hunter DJ, Spiegelman D, Adami HO, van den Brandt PA, Folsom AR, Goldbohm RA, et al. Non-dietary factors as risk factors for breast cancer, and as effect modifiers of the association of fat intake and risk of breast cancer. Cancer Causes Control 1997;8:49-56.   DOI
16 Clavel-Chapelon F, Group EN. Cumulative number of menstrual cycles and breast cancer risk: results from the E3N cohort study of French women. Cancer Causes Control 2002;13:831-838.   DOI
17 Hosseinzadeh M, Eivazi Ziaei J, Mahdavi N, Aghajari P, Vahidi M, Fateh A, et al. Risk factors for breast cancer in Iranian women: a hospital-based case-control study in tabriz, iran. J Breast Cancer 2014;17:236-243.   DOI
18 Alzubadiy MW, Almohaidi AM, Sultan AA, Abdulhameed LQ. Evaluation of E-selectin rs 5367 C/T polymorphism in Iraqi diabetic foot patients. J Phys Conf Ser 2019;1294:062021.
19 Al Hasnawi AY, Almohaidi AM, Yaser LA. Polymorphisms of Eselectin gene in the Arab Iraqi patients with diabetes mellitus type 2. Diyala J Pure Sci 2017;13:121-137.   DOI
20 Kontogianni P, Zambirinis CP, Theodoropoulos G, Gazouli M, Michalopoulos NV, Flessas J, et al. The impact of the stromal cell-derived factor-1-3'A and E-selectin S128R polymorphisms on breast cancer. Mol Biol Rep 2013;40:43-50.   DOI
21 Panoussopoulos GS, Theodoropoulos G, Michalopoulos NV, Gazouli M, Flessas J, Taka S, et al. Analysis of E-selectin S128R gene polymorphism in pancreatic cancer. J Surg Oncol 2010; 102:604-607.   DOI
22 Wang X, Zhang J, Du X, Song M, Jia C, Liu H. Association of A561C and G98T polymorphisms in E-selectin gene with coronary artery disease: a meta-analysis. PLoS One 2013;8:e79301.
23 Xia HZ, Du WD, Wu Q, Chen G, Zhou Y, Tang XF, et al. E-selectin rs5361 and FCGR2A rs1801274 variants were associated with increased risk of gastric cancer in a Chinese population. Mol Carcinog 2012;51:597-607.   DOI
24 Havasi V. Potential role of cystic fibrosis genetic modifier factors in congenital bilateral absence of the vas deferens. PhD dissertation. Budapest: Semmelweis University, 2013.
25 Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, et al. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res 2011;71:7683-7693.   DOI
26 O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 2002;38:2252-2257.   DOI
27 Dong Y, Guo M, Wang Z. Clinical significance of measurements of changes of serum e-cad, sICAM-I, L-Selectin and VEGF levels after operation in patients with ovarian cancer. Fangshe Mianyixue Zazhi 2008;21:268-270.
28 Izycka A, Jablonska E, Izycki T, Chyczewska E. Expression of L-selectin on the surface of neutrophils stimulated by TNF-alpha and level of sL-selectin in serum of patients with lung cancer. Pol Merkur Lekarski 2005;18:62-65.
29 Kiersnowska-Rogowska B, Izycka A, Jablonska E, Rogowski F, Parfienczyk A. Estimation of L-selectin expression on neutrophils and level of soluble L-selectin form in serum of patient with chronic myelogenic leukemia. Przegl Lek 2006;63:756-758.